IP Library › Granted Patent US 7,820,789
Granted Patent B2
US 7,820,789 · App. 11/568,802 · Granted Oct 26, 2010

Mutant pneumolysin proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,820,789
App. No.
11/568,802
Granted
Oct 26, 2010
Kind
B2
Abstract

The invention relates to immunogenic compositions comprising mutant Streptococcus pneumoniae pneumolysin proteins. The invention further relates to such proteins and nucleic acids encoding these proteins. In particular embodiments, the invention is directed to an isolated mutant pneumolysin (PLY) protein, wherein the mutant PLY protein differs from the wild-type PLY protein of SEQ ID NO:1 presence of a mutation within the region of amino acids 144 to 161 of the wild type such that the toxicity of the mutant is reduced relative to that of the wild-type protein. In particular embodiments, the mutant PLY protein differs from the wild-type protein by the substitution or deletion of amino acids including the deletion of two adjacent amino acids within the region of amino acids 144 to 151 of the wild-type sequence.

Claims (40)

1. An isolated mutant pneumolysin (PLY) protein comprising at least 95% sequence identity to a wild type PLY protein set forth in SEQ ID NO: 1, wherein one or more amino acids within the region of amino acids 144 to 151 of SEQ ID NO: 1 is deleted and wherein the isolated mutant PLY protein has reduced toxicity compared to the wild-type PLY protein.

2. The protein of claim 1 , wherein alanine 146 of SEQ ID NO: 1 is deleted.

3. The protein of claim 1 , wherein at least one amino acid substitution or deletion is in one or more regions of amino acids selected from the group consisting of:

(a) 257-297,

(b) 367-397; and

(c) 424-437 of SEQ ID NO: 1.

4. A composition comprising the protein of claim 1 , in a physiologically acceptable adjuvant, diluent or carrier.

5. The protein of claim 1 , wherein two adjacent amino acids within the region of amino acids 144 to 151 of SEQ ID NO:1 are deleted.

6. The protein of claim 5 , wherein amino acids valine 144 and proline 145 of SEQ ID NO: 1 are deleted.

7. The protein of claim 5 , wherein amino acids alanine 146 and arginine 147 of SEQ ID NO: 1 are deleted.

8. The protein of claim 5 , wherein amino acids methionine 148 and glutamine 149 of SEQ ID NO: 1 are deleted.

9. The protein of claim 5 , wherein amino acids tyrosine 150 and glutamic acid 151 of SEQ ID NO: 1 are deleted.

10. An immunogenic composition comprising:

(a) a saccharide, oligosaccharide, polysaccharide, peptide, polypeptide or protein; and

(b) the isolated mutant PLY protein of claim 1 in a physiologically acceptable adjuvant, diluent or carrier.

11. The immunogenic composition of claim 10 , wherein the saccharide, oligosaccharide or polysaccharide is derived from Streptococcus pneumoniae.

12. The immunogenic composition of claim 11 , wherein there are a plurality of Streptococcus pneumoniae serotypes.

13. The immunogenic composition of claim 10 , wherein at least one amino acid substitution or deletion is in one or more regions of amino acids selected from the group consisting of:

(a) 257-297,

(b) 367-397; and

(c) 424-437 of SEQ ID NO: 1.

14. The immunogenic composition of claim 10 , wherein two adjacent amino acids within the region of amino acids 144 to 151 of SEQ ID NO: 1 are deleted.

15. The immunogenic composition of claim 14 , wherein amino acids valine 144 and proline 145 of SEQ ID NO:1 are deleted.

16. The immunogenic composition of claim 14 , wherein amino acids alanine 146 and arginine 147 of SEQ ID NO:1 are deleted.

17. The immunogenic composition of claim 14 , wherein amino acids methionine 148 and glutamine 149 of SEQ ID NO:1 are deleted.

18. The immunogenic composition of claim 14 , wherein amino acids tyrosine 150 and glutamic acid 151 of SEQ ID NO:1 are deleted.

19. An immunogenic conjugate comprising:

(a) a saccharide, oligosaccharide, polysaccharide, peptide, polypeptide or protein; and

(b) the isolated mutant pneumolysin (PLY) protein of claim 1 .

20. The immunogenic conjugate of claim 19 , wherein the saccharide, oligosaccharide or polysaccharide is derived from Streptococcus pneumoniae.

21. The immunogenic conjugate of claim 19 , wherein at least one amino acid substitution or deletion is in one or more regions of amino acids selected from the group consisting of:

(a) 257-297,

(b) 367-397; and

(c) 424-437 of SEQ ID NO: 1.

22. The immunogenic conjugate of claim 19 , wherein alanine 146 of SEQ ID NO: 1 is deleted.

23. The immunogenic conjugate of claim 19 , wherein two adjacent amino acids within the region of amino acids 144 to 151 of SEQ ID NO: 1 are deleted.

24. The immunogenic conjugate of claim 23 , wherein amino acids valine 144 and proline 145 of SEQ ID NO: 1 are deleted.

25. The immunogenic conjugate of claim 23 , wherein amino acids alanine 146 and arginine 147 of SEQ ID NO: 1 are deleted.

26. The immunogenic conjugate of claim 23 , wherein amino acids methionine 148 and glutamine 149 of SEQ ID NO: 1 are deleted.

27. The immunogenic conjugate of claim 23 , wherein amino acids tyrosine 150 and glutamic acid 151 of SEQ ID NO: 1 are deleted.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2011
From: KIRKHAM, LEA-ANN; MITCHELL, TIMOTHY JOHN
To: THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW
Reel/Frame 026895/0219 →
Priority Claims (1)
GB 0410220.8 · May 7, 2004 · national
Continuity (2)
Provisional Application 6056941500 · May 7, 2004
Related Publication 20080112964A1 · May 15, 2008